| [1] |
Collaboration; ERF, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies[J]. Lancet ,2010, 375: 2215-2222.
|
| [2] |
Erqou S, Lee CT, Suffoletto M, et al. Association between glycated haemoglobin, the risk of congestive heart failure in diabetes mellitus: systematic review, meta-analysis[J]. Eur J Heart Fail, 2013, 15:185-193.
|
| [3] |
Group; DCaCTR, D M Nathan, S Genuth, et al. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus[J].N Engl J Med,1993,329: 977-986.
|
| [4] |
Group UPDSU. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. The Lancet,1998,352: 837-853.
|
| [5] |
Group TAtCCRiDS. Effects of Intensive Glucose Lowering in Type 2 Diabetes[J].N Engl J Med 2008,358: 2545-2559.
|
| [6] |
Group TAC. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes[J].N Engl J Med,2008,358: 2560-2572.
|
| [7] |
William Duckworth, Carlos Abraira, Thomas Moritz, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes[J].N Engl J Med,2009,360: 129-139.
|
| [8] |
Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2015,372: 2197-2206.
|
| [9] |
Rury R. Holman, F.R.C.P., Sanjoy K. Paul PD, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes[J].N Engl J Med,2008,359: 1577-1589.
|
| [10] |
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J].European heart journal,2020,41: 255-323.
|
| [11] |
Association; AD. Diabetes Advocacy: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Supplement 1): 182-183.
|
| [12] |
Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians[J].Ann Intern Med ,2018,168: 569-576.
|
| [13] |
Lee AK, Warren B, Lee CJ, et al. The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes[J].Diabetes Care,2018,41: 104-111.
|
| [14] |
Steven E. Nissen MD and and Kathy Wolski MPH. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N Engl J Med,2007,356: 2457-2471.
|
| [15] |
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J].N Engl J Med,2013,369: 1317-1326.
|
| [16] |
Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors[J].Circulation,2017, 136: 849-870.
|
| [17] |
Ussher JR and Drucker DJ. Cardiovascular biology of the incretin system[J].Endocr Rev,2012, 33: 187-215.
|
| [18] |
Ferraro RA, Nass CM, Dudum R, et al. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes[J].Am J Med,2019,132: 1027-1031.
|
| [19] |
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J].N Engl J Med ,2016,375: 311-322.
|
| [20] |
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med,2016,375: 1834-1844.
|
| [21] |
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial[J].The Lancet ,2019,394: 121-130.
|
| [22] |
Ahmed HM, Khraishah H and Cho L. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials[J]. European heart journal,2018,39: 2368-2375.
|
| [23] |
Ferrannini E and Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects[J].Nat Rev Endocrinol,2012,8: 495-502.
|
| [24] |
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes[J].N Engl J Med,2015,373: 2117-2128.
|
| [25] |
Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control[J].Circulation,2018,138: 1904-1907.
|
| [26] |
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J].N Engl J Med ,2019,380: 347-357.
|
